Key Events This Week
4 May: Technical momentum shifts amid mixed signals
5 May: Upgrade to Hold rating on improved valuation and technicals
5 May: Valuation parameters signal renewed price attractiveness
8 May: Week closes at Rs.5,576.80 (+4.14%) outperforming Sensex

Alkem Laboratories Ltd Upgraded to Hold by MarketsMOJO on Improved Valuation and Technicals
2026-05-05 08:51:49Alkem Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting improvements in valuation metrics and technical indicators despite flat recent financial performance. The mid-cap pharmaceutical company’s revised Mojo Score of 50.0 and Hold grade mark a significant shift driven by a combination of factors including enhanced valuation attractiveness, evolving technical trends, stable financial fundamentals, and solid quality parameters.
Read full news article
Alkem Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-05-05 08:01:18Alkem Laboratories Ltd has witnessed a notable improvement in its valuation parameters, prompting a reclassification from a Sell to a Hold rating with an upgraded valuation grade from fair to attractive. This shift reflects a more compelling price-to-earnings (P/E) and price-to-book value (P/BV) ratio relative to its historical averages and peer group, signalling a potential inflection point for investors assessing the pharmaceutical sector’s mid-cap landscape.
Read full news article
Alkem Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-05-04 08:02:17Alkem Laboratories Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend as of late April 2026. Despite a modest day gain of 1.14%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the recent technical developments and what they imply for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news articleAlkem Laboratories Gains 3.35%: 5 Key Factors Driving the Week’s Mixed Momentum
2026-05-02 13:03:23
Key Events This Week
27 Apr: Sharp open interest surge and 2.29% price gain
28 Apr: Formation of Death Cross and technical downgrade
29 Apr: Mojo Grade downgraded to Sell amid valuation concerns
30 Apr: Bearish momentum intensifies with 1.26% price decline

Alkem Laboratories Ltd Faces Bearish Momentum Amid Technical Downgrade
2026-04-30 08:03:06Alkem Laboratories Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish territory. This downgrade in technical outlook accompanies a 1.26% decline in the stock price, reflecting growing investor caution amid mixed signals from momentum oscillators and moving averages.
Read full news article
Alkem Laboratories Downgraded to Sell Amid Technical and Valuation Concerns
2026-04-29 08:16:14Alkem Laboratories Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 28 Apr 2026. This revision reflects a combination of deteriorating technical indicators, a shift in valuation metrics, and a subdued financial trend, despite the company’s strong long-term returns and solid management efficiency.
Read full news article
Alkem Laboratories Ltd Faces Mildly Bearish Momentum Amid Technical Shifts
2026-04-29 08:03:22Alkem Laboratories Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Recent technical indicators including MACD, RSI, moving averages, and Bollinger Bands suggest a nuanced market sentiment, prompting a downgrade in its Mojo Grade from Hold to Sell as of 28 April 2026.
Read full news article
Alkem Laboratories Ltd Forms Death Cross, Signalling Potential Bearish Trend
2026-04-28 18:00:25Alkem Laboratories Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting a deterioration in the stock’s medium-term momentum and raising concerns about long-term weakness in the Pharmaceuticals & Biotechnology sector.
Read full news articleRegulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
05-May-2026 | Source : BSEPlease find Attached herewith Disclosure under Regulation 30 of SEBI(LODR) 2015.
US FDA Inspection At CompanyS Manufacturing Facility Located At Amaliya Daman
02-May-2026 | Source : BSEPlease find attached herewith Intimation about US FDA Inspection at Company s manufacturing facility located at Amaliya Daman.
Announcement under Regulation 30 (LODR)-Cessation
24-Apr-2026 | Source : BSEPlease find attached herewith intimation for Change in Key Managerial Personnel - Resignation of Chief Executive Officer
Corporate Actions
No Upcoming Board Meetings
Alkem Laboratories Ltd has declared 2150% dividend, ex-date: 20 Feb 26
No Splits history available
No Bonus history available
No Rights history available






